Agios Pharm (AGIO NASDAQ) stock market data APIs
$27.3999
-0.01(-0%)
as of December 4, 2025
Try our APIs with
free plan!
Agios Pharm Financial Data Overview
Price chart is built with
Anychart
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Prev. Close
27.3999
Open
27.3944
High
27.7166
Low
27.3383
52 wk Range
22.24-62.45
Market Cap
1 603 M
Shares Outstanding
58 314 K
Revenue
44 791 K
EPS
-1.78
Beta
0.836
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Agios Pharm (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Agios Pharm data using free add-ons & libraries
Get Agios Pharm Fundamental Data
Agios Pharm Fundamental data includes:
- Net Revenue: 44 791 K
- EBITDA: -470 312 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -1.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Agios Pharm News
New
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight
DelveInsight Business Research LLP The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches,...
Biotech Stocks Facing FDA Decision In December 2025
(RTTNews) - Every month, several health-awareness campaigns are conducted, and December, despite being a festive holiday season, is no different. Two major global and national health campaigns are rec...
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Per...
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
